STAT proteins are activated by phosphorylation at speci®c tyrosine residue at the carboxy-terminus which is required for dimer-formation, nuclear translocation, DNA binding and transcriptional activity in cells treated with cytokines and growth factors. Recent studies have indicated that STATs are also phosphorylated by MAPK, or extracellular signal-regulated kinase (ERK) on serine. We investigated the role of ERK on the regulation of STAT activity. Here, we report that ERK2 activated by its upstream kinase, MEK1, represses Stat3 transcriptional activity induced by Src or Jak-2. To unravel the mechanism of repression, we further showed that Stat3 DNA binding activity and its tyrosine phosphorylation are also inhibited under the same conditions. ERK2 phosphorylates Stat3 on three serinecontaining peptides and decreases its tyrosine phosphorylation induced by EGF treatment. We also detected an association of ERK2 and Stat3 in vivo which is modulated positively by activation of ERK2, but negatively by Jak2. We propose that MAP kinase cascade may negatively regulate Stat3 activities by decreasing its tyrosine phosphorylation and also possibly by association.
Introduction
STATs, act as signal transducers and transcriptional activators in the cytokine and growth factor treated cells (reviewed in Darnell et al., 1994; Ihle, 1996) . Janus protein tyrosine kinases (JAKs) associate with cytokine receptors which lack intrinsic tyrosine kinase activity and become activated upon cytokine stimulation. Activated JAKs phosphorylate the target tyrosine residues in the receptors (Silvennoinen et al., 1993; Stahl et al., 1994) where STATs are selectively recruited through their SH2 domain and then phosphorylated by JAKs on a conserved tyrosine residue at the carboxy terminus (Heim et al., 1995; Stahl et al., 1995) . Such tyrosine phosphorylation is required for the formation of homo-or heterodimers through their phosphorylated tyrosine residues and SH2 domains, nuclear translocation, binding to cognate DNA response elements and transactivation of gene expression Ihle, 1996) . Stat1 was the ®rst STAT protein identi®ed in the interferon (IFN) signaling pathways and was later found to be activated by other cytokines and growth factor EGF Shuai et al., 1992; Fu and Zhang, 1993) . Stat3 (also known as acutephase response factor APRF) which shares 52.5% amino acid identity with Stat1 and has similar size and structure, is mainly induced by growth factors, such as platelet-derived growth factor (PDGF), colony-stimulating factor-1 (CSF-1), EGF, and a number of cytokines, including IFN-a and interleukin-6 (IL-6) (Akira et al., 1994; Zhong et al., 1994) . Based on sequence alignment with Stat1, which is phosphorylated on Tyr-701 in IFN-g-treated cells . Tyr-705 of Stat3 was identi®ed as the phosphorylation site for JAKs in the cytokine signaling (Kaptein et al., 1996) . However, Jaks may not be required for the activation of Stat3 by growth factors such as EGF and PDGF which bind to their receptors with intrinsic tyrosine kinase activity. Instead, tyrosine kinase activity of the receptors are important for Stat3 activation (Leaman et al., 1996) . Furthermore, it has been reported that Stat3 is constitutively phosphorylated on tyrosine in the Srctransformed cells, and Src is required for the activation of Stat3 by CSF-1, suggesting that Src may be speci®cally involved in Stat3 activation during growth factor signaling (Yu et al., 1995; Cao et al., 1996 , Chaturvedi et al., 1997 .
The Ras/Raf/MAPK pathway is a major signaling pathway of growth factors and cytokines (reviewed in Hill and Triesman, 1995) . The cascade involves transient formation of the ras-GTP and activation of raf kinase at the cell membrane to activate MAPK kinase (MAPKK or MEK) which in turn activates MAPK through dual phosphorylation on threonine and tyrosine residues (Leevers et al., 1994; Stokoe et al., 1994) . Activated MAPK then translocates into the nucleus and phosphorylates the ternary complex factor TCF (Shaw et al., 1989) which activates the expression of immediate-early genes, such as c-fos and egr-1 (reviewed in Triesman, 1995) . Recently, it has been reported that phosphorylation of STATs on serine may also be important for their functions (Zhang et al., 1995) . A conserved phosphorylation site of MAPK/ERK is identi®ed within the COOH-terminus of Stat1a, Stat3, Stat4 and Stat5 (Wen et al., 1995) and Stat3 is shown to be phosphorylated by ERK on serine 727 in response to growth factors (Chung et al., 1997) . These reports suggest that MAPK cascade may be involved in regulating the STAT function. Since the MAPK cascade is a major signaling pathway involved in cell growth and dierentiation, and both the MAPK and the Stat3 are activated by a series of overlapping growth factors and cytokines, we investigated the role of MAPK on Stat3 activity. Here we report that ERK2 negatively regulates Stat3 transcription activity, DNA binding, and its tyrosine phosphorylation. We further show that ERK2 associates with Stat3 which is modulated positively by the activation of ERK2, but negatively by tyrosine phosphorylation of Stat3. ERK2 phosphorylates Stat3 on three serine-containing peptides and decreases its tyrosine phosphorylation. We propose that the MAP kinase cascade negatively regulates Stat3 activities by regulating its phosphorylation as well as by association.
Results

Repression of Stat3 transcription activity by ERK2 activated by MEK1
A consensus sequence of MAPK phosphorylation, PMSP, was observed at Ser-727 in the COOHterminus of Stat3, and mutation of this site decreased Stat3 transcriptional activity (Wen et al., 1995) . To further investigate the eect of ERK2 on Stat3 function, we ®rst examined how ERK2 aected Stat3 transactivation. Since tyrosine phosphorylation is a prerequisite for STAT activities Schindler and Darnell, 1995; Ihle, 1996) and the tyrosine kinase Src speci®cally increases Stat3 tyrosine phosphorylation and its DNA binding (Yu et al., 1995; Cao et al., 1996) , we ®rst tested whether Src can stimulate Stat3 transcriptional activity and how ERK2 aects such activity with transient transfection experiments. COS-1 cells, which express very low endogenous Stat3 (Wen et al., 1995) , were cotransfected with a CAT reporter plasmid containing three copies of a high anity binding site of Stat3, hSIE, together with a Stat3 expression plasmid in the absence or presence of Src expression plasmid. The cells were lysed and the CAT activity assayed. The CAT activity was low in the cells transfected with Stat3 without Src, but increased by ninefold in the presence of Src (Figure 1a ), indicating that Src indeed stimulates Stat3 transcriptional activity. It is known that ERK2 is phosphorylated and activated by its upstream kinase MEK1. To examine the eect of ERK2 on Stat3 transactivation stimulated by Src, plasmids expressing ERK2 (pCDNA3.p42) and MEK1D, a constitutively activated MEK1 (Mansour et al., 1994) , were co-transfected either alone or together, in the absence or presence of Src. The results showed that the expression of ERK2 or MEK1D without Src did not stimulate Stat3 activity as expected. Surprisingly, the Src-stimulated Stat3 activity was decreased by ERK2 or MEK1 alone, and completely inhibited by co-transfection of ERK2 and MEK1 together (Figure 1a) . The repression was recovered more than 75% when ERK2 was cotransfected with a mutant MEK1 (MEK1D
7
) which lacks the kinase activity ( Figure 1a) . To exclude the possibility that the repression was due to the highly activated MEK1D, a normal MEK1 was examined and the repression on Stat3 transcriptional activity remained (data not shown). These results demonstrate that activated ERK2 by MEK1 represses Stat3 transcriptional activity speci®cally.
To con®rm these results, similar experiments were performed in NIH3T3 cells. Although the basal level of Stat3 activity was higher than that in the COS-1 cells, Stat3 activity was stimulated by Src and repressed by co-expression of MEK1D and ERK2 (Figure 1b ) in a similar pattern to that in the COS-1 cells, indicating that the inhibition is not cell type restricted.
Since JAKs are the upstream kinases for STAT protein tyrosine phosphorylation in response to certain cytokines, we also examined the eect of ERK2 on Stat3 transactivation stimulated by Jak2. Src was replaced by Jak2 in transient transfection experiments. The results showed that the Jak2 stimulated Stat3 activity was dramatically reduced, but not completely inhibited (approximately 60% inhibition) by ERK2 and MEK1D together (Figure 1c ). These data demonstrate that ERK2 activated by MEK1 negatively regulates Stat3 transcriptional activity mediated by either Src or Jak2.
To exclude the possibility of a non-speci®c inhibitory eect of MEK1D and ERK2, another set of eector and reporter genes were examined. The ternary complex factor TCF is one of the main targets of Ras/MAP kinase pathway (Shaw et al., 1989; Hill and Triesman, 1995) . ERK2 is phosphorylated by MEK1, and in turn phosphorylates TCF on serine residues. The active TCF binds to SRF and SRE to form a ternary complex, and induces the expression of immediate-early genes such as c-fos and egr-1. Since egr-1 contains six SREs in its promoter region and is inducible by various growth factors Tsai-Morris et al., 1988) , we tested the eect of ERK2 and MEK1 on egr-1 transcription. pEgr-1.1.2-CAT containing the 1.2 kb promoter sequence of egr-1 (Tsai-Morris et al., 1988) upstream of CAT gene was used as a reporter. ERK2, MEK1D and a member of the TCF family, Elk-1, (Marais et al., 1993) , were either transfected alone or co-transfected in various combinations with the reporter into NIH 3T3 cells, and the CAT activities were assayed. Very low CAT activity was observed with ERK2 alone, but increased by 39-fold in cells co-transfected with ERK2 and MEK1D together, and further increased by 62-fold when the exogenous Elk-1 was included (Figure 1d , left panel). The activation of egr-1 promoter by MEK1D and ERK2 in the absence or the presence of Elk-1 was also observed in transfected COS-1 cells (Figure 1d , right panel). These results excluded the possibility of a non-speci®c inhibitory eect of MEK1D and ERK2 on Stat3 SIE-reporter in these cells.
Inhibition of DNA binding activity of Stat3 by ERK2
In order to understand the mechanism of the repression, we tested whether ERK2 activated by MEK1D aects the Stat3 DNA binding activity. COS-1 cells were transfected as described in Figure  1a without the reporter plasmid. The nuclear extracts were prepared and the mobility shift assay was performed using hSIE as a probe. Activated Stat3 and Stat1 form three complexes with SIE (Sadowski et al., 1993) 
Inhibition of Stat3 tyrosine phosphorylation by ERK2
We next examined the tyrosine phosphorylation status of Stat3 in the transfected COS-1 cells. A plasmid 
ERK2 associates with Stat3 in v-Src transformed cells
To further study the mechanism of the repression, we tested whether Stat3 and ERK2 are physically associated. IND-REF-src, a v-Src transformed rat embryo ®broblast line, in which the v-Src expression was driven by a dexamethasone (DM)-inducible promoter was chosen since both Stat3 and ERK2 are activated by expression of v-Src. Lysates from the DM-treated or untreated cells were immunoprecipitated (IP) with preimmune serum (Figure 4 , lanes 1 and 2), anti-Stat3 (lanes 3 and 4), or anti-ERK2 (lanes 5 and 6) antibody, and the immunoprecipitates were separated by SDS ± PAGE, transferred to PVDF membrane, and ®rst blotted (BLOT) with anti-ERK2 antibody ( Figure 4a ). As shown in Figure 4a , while ERK2 was detected when immunoprecipitated with its own antibody (lanes 5 and 6), it also co-precipitated with the Stat3 antibody, albeit weakly, in both DM-induced or uninduced cells (lanes 3 and 4). The blot was stripped and re-probed with the anti-Stat3 antibody ( Figure 4b ). In addition to its own antibody ( Figure 4b , lanes 3 and 4), Stat3 was also shown to be co-precipitated with anti-ERK2 antibody (lanes 5 and 6). As a control, preimmune serum of Stat3 did not immunoprecipitate Stat3 or ERK2 (Figure 4a and b, lanes 1 and 2). These data indicate that Stat3 is associated with ERK2 in vivo.
Eects of Stat3 phosphorylation on Stat3/ERK2 association.
Since Stat3 is phosphorylated on Tyr-705 and Ser-727 in response to growth factors and cytokines, we investigated how the phosphorylation aects its interaction with ERK2. Wild-type Stat3 was tagged to the COOHterminus of hemagglutinin epitope (HA-ST3) and its point mutants HA-S1 (Ser-727 to alanine) and HA-Y1 (Tyr-705 to phenylalanine) were constructed. These Stat3 constructs were co-transfected with ERK2 with or without Jak2 expression plasmids into COS-1 cells. The lysates were immunoprecipitated with anti-ERK2 antibody, and the immunocomplex was probed with an anti-HA monoclonal antibody. As shown in Figure 5a , in the absence of Jak2, wild type Stat3 (HA-ST3) and Tyr-705 mutant (HA-Y1) co-precipitated with ERK2 antibody (lanes 3 and 5) almost equally. However, the Ser-727 mutant (HA-S1) showed a 60% decrease in binding to ERK2 (lane 7) and no Stat3 protein was detected in the cells co-transfected with ERK2 and the control HA vector (lane 1). Interestingly, the binding of ERK2 to the wild type Stat3 (HA-ST3) was inhibited almost completely with co-expression of Jak2 (lane 4), whereas the binding to the Tyr-705 mutant (HA-Y1) remained unchanged with or without Jak2 expression (lane 6). The weak binding of Ser-727 mutant (HA-S1) to ERK2 was completely abolished (lane 8) in the presence of Jak2. The blot was stripped and reprobed with anti-ERK2 antibody showing an approximately Figure 5a , upper panel) was a protein reacting with the anti-HA antibody non-speci®cally. Similar results were obtained when Jak2 was replaced with a Src expression plasmid in the above experiments (data not shown). Together, these results suggest that Ser-727 is important for ERK2 association, whereas tyrosine phosphorylation on Tyr-705 either by Jak2 or Src kinase, may negatively regulate the binding of Stat3 to ERK2. The eects of these mutants on the ERK2 association are likely to be due to phosphorylation. However, it cannot be ruled out that conformational changes of the mutant proteins caused by the mutation or some other unknown factor(s) may aect the anity of ERK2 binding. The expression levels of ERK2 and Stat3 proteins in each transfected sample were measured by Western blot analysis of the whole cell extract. Only a small variation in Stat3 expression was observed with approximately a 10% increase in HA-Y1 (Figure 5b , lanes 5 and 6) and a 10% decrease in HA-S1 (lanes 7 and 8) compared to the wild type (lanes 3 and 4), and no change was observed in the expression of ERK2 in each sample (not shown). This suggests that the dierential association of ERK2 and the Stat3 mutants is mainly due to the mutations themselves, and not the variation in the expression.
Eect of ERK2 phosphorylation on Stat3/ERK2 association
ERK2 is activated by dual phosphorylation on tyrosine and threonine in its activation motif TEY by stimulation of various growth factors and cytokines. We therefore tested the eect of ERK2 phosphorylation on the Stat3 association. COS-1 cells were cotransfected with ERK2 and the wild-type or the Tyr-705 mutant Stat3 and treated with tyrosine kinase inhibitors genistein and staurosporine, serine/threonine kinase inhibitor H7, or the serine/threonine phosphatase inhibitor okadaic acid for 1 h before harvesting. Both genistein (Figure 6a , lanes 4 ± 6) and staurosporine (lanes 7 ± 9) dramatically reduced the binding of ERK2 to the wild type (HA-ST3) and the Tyr-705 mutant (HA-Y1), whereas H7 did not aect the binding signi®cantly (Figure 6b , lanes 4 ± 6). In contrast, okadaic acid treatment enhanced the association of ERK2 with both the wild type and the Tyr-705 mutant (Figure 6b , upper panel, lanes 7 ± 9). Correspondingly, a basal level of tyrosine phosphorylation of the transiently expressed ERK2 (Figure 6a , lower panel, lanes 1 ± 3) was detected which was reduced by genestein and staurosporine treatments (lanes 4 ± 9), unaected by H7 (Figure 6b , lower panel, lanes 4 ± 6), and increased by okadaic acid (Figure 6b , lanes 7 ± 9). These data suggest that the level of ERK2 tyrosine The eect a speci®c inhibitor of MEK1, PD98059 (Dudley et al., 1995) , on association was also analysed. Transfected COS-1 cells were treated with the inhibitor for 1 h before harvesting and the ERK2/Stat3 association was examined. As illustrated in Figure  6c , PD98059 inhibited ERK2 phosphorylation (lanes 4 ± 6, lower panel) and also reduced ERK2 binding to wild type Stat3 and the Tyr-705 mutant (compare lanes 5 and 6 to the controls in lanes 2 and 3, upper panel). Next, we examined the eect of MEK1D on ERK2/Stat3 association by co-transfecting COS-1 cells with Stat3, ERK2 and MEK1. As shown in Figure 6d , unlike Jak2 and Src kinase which inhibited the association, MEK1 increased the association of ERK2 not only with the wild type Stat3 and Tyr-705 mutant (lanes 2 and 3), but also with the Ser-727 and the Tyr-705/Ser-727 double mutants (lanes 4 and 5). The later two bound to ERK2 poorly in the absence of MEK1D (Figure 5a and not shown). Strong tyrosine phosphorylation of ERK2 by MEK1D is shown at the bottom panel of Figure 6d . Together, these data indicate that inhibition of ERK2 phosphorylation by either tyrosine kinase inhibitors genistein and staurosporine or by the speci®c inhibitor of MEK1 reduces its association with Stat3, whereas increasing ERK2 phosphorylation by MEK1 or by inhibition of protein phosphatases enhances its binding ability to Stat3. The cells were treated with 10 mM of genistein (New England Biolabs) (lanes 4 ± 6), 10 mM of staurosporine (Clontech) (lanes 7 ± 9), or left untreated (lanes 1 ± 3), or (b) treated with either 25 mM of H7 (Biomol) (lanes 4 ± 6) or 0.5 mM of okadaic acid (OA, Biomol) (lanes 7 ± 9) for 1 h, or left untreated (lanes 1 ± 3). The cell lysates were immunoprecipitated with anti-ERK2 and probed with anti-HA antibodies (upper panels). The blots were stripped and re-probed with anti-phosphotyrosine antibody 4G10 (lower panels). The molecular mass markers are shown on the right. (c) Transfected cells were left untreated (lanes 1 ± 3) or treated with 10 mM of PD98059 (PD, New England Biolabs) for 1 h (lanes 4 ± 6) and the IP/BLOT experiment was performed as described in (a and b). . These results suggest that the association of these two proteins occurs mainly in the cytoplasm in the untreated cells, however, both proteins translocate into the nucleus and associate together after DM treatment. It appears that the association in the nucleus occurs with high anity, probably due to the presence of highly phosphorylated ERK2 in the nucleus. The results are in agreement to the observations described above showing that activation of ERK2 increases its binding to Stat3.
Phosphorylation of Stat3 by ERK2
We next investigated the phosphorylation of Stat3 by ERK2 and how such phosphorylation leads to the repression of Stat3 activity. COS-1 cells were transfected with pCMV-Stat3, with or without ERK2 in the absence or presence of MEK1D. The cells were labeled with 32 P-orthophosphate, treated with EGF or left untreated before harvesting, and immunoprecipitated with an anti-Stat3 antibody. The immunoprecipitates were resolved by SDS ± PAGE and transferred onto membrane, followed by autoradiography. As shown in Figure 8a , basal level of Stat3 phosphorylation was observed in the untreated cell (lane 1), enhanced slightly (1.7-fold) by co-transfection of ERK2 alone (lane 2) and increased signi®cantly (4.4-fold) by co-transfection of ERK2 and MEK1D (lane 5). EGF treatment (lane 3) also stimulated Stat3 phosphorylation strongly (7.6-fold, lane 3) which was slightly decreased (about 10%) when ERK2 was cotransfected (lane 4). To further study the phosphorylation, the in vivo labeled Stat3 was digested with trypsin and analysed by two-dimensional peptide mapping as described in the Materials and methods (Boyle et al., 1991) . A weak phosphopeptide (labeled as`a' in Figure 8b , panel I) was observed in the untreated cells, and increased slightly in ERK2 transfected cells (panel II), indicating that the transfected ERK2 without activation had little eect on Stat3 phosphorylation. Peptide`a' was strongly phosphorylated and two other peptides, labeled`b' and`d', were also phosphorylated, albeit weaker, in cells co-transfected with ERK2 and MEK1 (panel III). Similar pattern was observed in cells treated with EGF except for an additional spot (labeled as`c' in panel IV) which was a phosphotyrosine-containing peptide as demonstrated by phosphoamino acid analysis (Figure 8c) . Notably, phosphorylation of this spot was reduced 50% in the cells transfected with ERK2 and treated with EGF (compare`c' in panel V to panel IV). On the other hand, peptides`a' and`b', containing only phosphoserine remains almost unchanged (Figure 8b and c) . Since Ser-727 is the major phosphorylation site of ERK2 (Chung et al., 1997) , it is likely that peptide`a' contains Ser-727, whereas peptides`b' and`d' may contain minor phosphorylation sites of ERK2. Identi®cation of these sites is currently under investigation. Stat3 was not phosphorylated in cells transfected with MEK1D alone (data not shown). From these data, we conclude that: (1) ERK2 is the major serine/threonine kinase induced by EGF which not only phosphorylates Stat3 on Ser-727, but also on other sites; (2) the EGFinduced tyrosine phosphorylation was reduced by cotransfection of ERK2, which is consistent with our previous results (Figure 3 ) and further suggests that the ERK2 negatively regulates the tyrosine phosphorylation of Stat3. P-orthophosphate for 4 h at a ®nal concentration of 1 mCi/ml, left untreated (7) or treated with EGF (+), lysed in RIPA buer and immunoprecipitated with Stat3 antibody. The immunoprecipitates were separated by 7.5% SDS ± PAGE and transferred to a nitrocellulose membrane and autoradiographed as shown in (a). (b) The Stat3 band was excised, digested with typsin, and subjected to two-dimensional peptide mapping. U: untreated, EGF:EGF treated. (c) Spots a, b, and c were eluted and subjected to phosphoamino acid analysis. The intensity of the bands in (a) and spots in (b) was quantitated using BioRad GS700 Imaging Densitometer 
Discussion
The role of serine phosphorylation on Stat1 and Stat3 activities was ®rst reported by Zhang et al. (1995) showing the requirements of such phosphorylation for the DNA binding. Subsequently, the consensus phosphorylation site of MAPK in STATs (Ser-727 in both Stat1 and Stat3) was demonstrated to be required for the maximum transcription but not for the DNA binding activity through mutational studies on this site (Wen et al., 1995; Wen and Darnell, 1997) . Coprecipitation of Stat1 with ERK2 in the IFN-binduced cells and reduction of IFN-b-induced gene transcription by dominant negative mutant ERK2 were also reported (David et al., 1995) . These results suggested that MAPK acts as a positive signal in the regulation of STAT activity. Since both Stat3 and MAPK are phosphorylated and activated by growth factors, such as PDGF, EGF, and CSF-1, we investigated the role of MAPK phosphorylation on Stat3 function by testing the eect of ERK2 on Stat3 transcriptional activity. Unexpectedly, we found that expression of MAPK activated by its upstream kinase, MEK1, represses Stat3 transcriptional activity. Furthermore, its DNA binding and tyrosine phosphorylation were also inhibited. These data suggest MAPK negatively regulates Stat3 activity. Recently, two reports addressing the role of MAPK and the serine phosphorylation on STATs have been published. Chung et al. (1997) reported that Stat3 serine phosphorylation is mediated through an ERK-dependent pathway in response to EGF and negatively modulates its tyrosine phosphorylation. Our results are consistent with the report and further demonstrate that the negative eect on tyrosine phosphorylation results in the inhibition of its DNA binding and transcriptional activity. Serine phosphorylation of Stat3 in the IL-6-induced cells, however, was found to be ERKindependent as reported by the same group (Chung et al., 1997) . Another report by Zhu et al. (1997) indicated that MAPK is weakly activated in response to IFN-g and is not responsible for Stat1 serine phosphorylation. These data suggest the eect of serine phosphorylation on STATs could be a complicated issue. The individual STAT protein may be phosphorylated by dierent kinases in a liganddependent manner. Furthermore, dierent levels of the serine phosphorylation may lead to opposite eects on STAT activity. The precise eects of serine phosphorylation on STATs requires further studies.
To elucidate the possible mechanisms of the repression, we investigated Stat3 phosphorylation by ERK2 using two-dimensional peptide mapping. Three peptides were found to be phosphorylated on serine (`a',`b' and`d' in Figure 8b ) by activated ERK2 or EGF stimulation. The strong phosphorylated peptidè a' probably represents Ser-727 since it has been demonstrated to be the major phosphorylation site by ERK (Chung et al., 1997) and the identity of the other two is unknown. Peptide`c' is the only tyrosine phosphorylated peptide which is likely to contain Tyr-705 identi®ed previously (Kaptein et al., 1996) . Expression of transfected ERK2 in the EGF-treated cells did not further increase the serine phosphorylation, but instead, it reduced the tyrosine phosphorylation (Figure 8b , panels IV and V). Therefore, the repression of Stat3 activity by ERK2 is probably the result of decreased tyrosine phosphorylation, and not by directly increasing the serine phosphorylation.
To further address the relation between serine and tyrosine phosphorylation, we examined the time course of Stat3 phosphorylation in response to EGF treatment. The phosphoamino acid analysis of in vivo-labeled Stat3 showed that phosphorylation on tyrosine appeared at 30 s, increased signi®cantly at 2 and 8 min and continued to increase at 15 min, whereas a constitutive serine phosphorylation was observed in the untreated cells which increased at 8 min and was further enhanced at 15 min (data not shown). These results are consistent to those observed in IL-6-induced HepG2 cells (LuÈ tticken et al., 1995) and IFN-g-induced cells for Stat1 (Zhu et al., 1997) , indicating that tyrosine phosphorylation occurs prior to serine. These data support the hypothesis that serine phosphorylation may be involved in the inactivation of STAT activity.
We further investigated the mechanism of ERK2 inhibition on Stat3 tyrosine phosphorylation by testing the interaction of ERK2 and Stat3 and demonstrated their association in vivo. To further characterize this association, we examined the eects of Stat3 and ERK2 phosphorylation on their association. MAPK recognition site on Stat3, Ser-727, is important for the association since mutation on this site reduced the association drastically. On the other hand, tyrosine phosphorylation by Jak2 or c-Src reduced the wild type, but not the Tyr-705 mutant of Stat3 binding to ERK2. An increase of ERK2 phosphorylation mediated by okadaic acid, enhances its binding to Stat3 (Figure 6b) . Furthermore, ERK2 phosphorylation by its upstream kinase MEK1 increased not only its association with the wild type Stat3, but also with the Ser-727 mutant which could not associate with ERK2 in the absence of MEK1 in the uninduced cells (Figure 6d ). This suggests a high anity binding of Stat3 with the activated ERK2 which can override the requirement of the serine phosphorylation. In agreement with this, we also detected a high anity association appearing in the nucleus after v-Src expression. Therefore, it appears that two types of binding exist: unphosphorylated ERK2 binds Stat3 with low anity in unstimulated cells in the cytoplasm which can be replaced by the other Stat3 molecule, whereas phosphorylated ERK2 binds to Stat3 with high anity, possibly in the nucleus, which negatively modulates Stat3 activity by decreasing its Tyrphosphorylation through an as yet unknown mechanism. Surprisingly, unlike c-Src and Jak2, v-Src expression seems not to aect Stat3/ERK2 association in the v-Src transformed cells. The reason for this is unknown and one possible explanation could be the strong phosphorylation of ERK2 by v-Src which leads to an increase in the association.
Based on these data, we propose the following model: ERK2 associates with Stat3 in the untreated cells and may phosphorylate Stat3 on serine at low level that is required for the full transcriptional activity of Stat3. After growth factor stimulation, the ERK2/ Stat3 association is rapidly disrupted by formation of Stat3 dimer in the cytoplasm. Meanwhile, ERK2 itself is also activated which negatively modulates Stat3 activity by further phosphorylation and/or by tight association with Stat3. Further experiments are being carried out to address this hypothesis.
Materials and methods
Construction of expression plasmids
The expression plasmids of Stat3, pRc/CMV-Stat3 (Zhong et al., 1994) , and Stat1, pMNC-91 , were obtained from Dr JE Darnell (The Rockefeller University, USA). Glutathione-S-transferase (GST)-Stat3 fusion protein (GST-Stat3) containing an almost full-length Stat3 was constructed as described previously . Point mutations of GST-Stat3 were prepared by using the PCR-based site-directed mutagensis kit ExSite TM (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. The resultant plasmids contain mutations at Tyr-705 (replaced by Phe), Ser-727 (replaced by Ala), or double mutations at both positions and named as GST-Y1, GST-S1, or GST-YS1. All the point mutations were con®rmed by DNA sequencing. Stat3 expression plasmids for transfection were prepared by inserting the EcoRI ± XhoI fragments containing amino acids 28 ± 770 of Stat3 from GST-Stat3 or GST-Stat3 mutants into expression vector pcDNA3 (Invitrogen, San Diego, CA, USA). The BamHI ± XhoI fragments from pcDNA3-Stat3 constructs were inserted into plasmid pXJ40-HA (a hemagglutinin epitope-tagged expression vector from Dr E Manser of our institute), so that the HA was tagged at NH 2 -terminal of Stat3 and its mutants. The plasmids were named as HA-ST3, HA-Y1, HA-S1 and HA-YS1 respectively. The expression vectors containing wild type chicken Src (pSGTsrc K + ) and kinase inactive Src (pSGTsrcK 7 ) were obtained from Dr SA Courtneidge (Sugen Inc., Redwood City, CA, USA) as described by Barone and Courtneidge (1995) . Wild type Jak2 and the kinase defective mutant of Jak2 expression vectors (Silvennoinen et al., 1993) were obtained from Dr O Silvennoinen (University of Helsinki, Finland) and the Elk-1 expression plasmid MLV-Elk-1 (Marais et al., 1993) was obtained from Dr R Treisman (Imperial Cancer Research Fund, London, UK). The ERK2 expression plasmid pcDNA3.ERK2 was prepared by inserting the ERK2 coding sequence from plasmid pBA4 (Her et al., 1991) into pcDNA3.
The plasmid MEK1D (DN2/S218E/S222D) expresses a constitutively active MAPK kinase as described by Mansour et al. (1994) , and the mutant MEK1D 7 which lacks the kinase activity with substitution of lysine 97 by methionine, were obtained from Dr A Whitmarsh (University of Massachusetts Medical School, Worcester, MA, USA). Plasmid expressing normal MEK1 was obained from Dr. Richard Jove (University of South Florida, Tampa, FL, USA). The reporter plasmid pSIE-CAT for CAT assay was prepared by inserting three copies of the high anity SIE consensus sequence (TTCCCGTAA) upstream of a c-fos minimal promoter followed by the CAT gene in plasmid pFOSCATD56 (Gilman et al., 1986) .
DNA transfection, CAT assay and mobility shift DNA binding assay COS-1 and NIH3T3 cells were grown in DMEM with 10% fetal calf serum purchased from Gibco BRL Life Technologies (Grand Island, NY, USA) or Hyclone (Logan, UT, USA). Transfection of the plasmids into COS-1 cells was performed by the calcium phosphate-DNA coprecipitation method as described previously (Gorman et al., 1982) . For CAT-assays, the cells were co-transfected with 4 mg CAT-containing reporter plasmids, 5 mg of expression plasmids, and 2 mg of pCMV-b-gal containing bacterial b-galactosidase gene. The total amount of DNA transfected was kept constant at 20 mg per plate with control plasmid pCMV-5. The cells were maintained in DMEM with 10% fetal calf serum and harvested 45 h after transfection. Transfection was also performed with lipofectamine reagent (GIBCO BRL Life Technologies, Gaithersburg, MD, USA) in NIH3T3 cells for CAT assays following the manufacturer's instruction. The cells were lysed in 0.25 M Tris-HCl (pH 8.0) with three`freeze-thaw' cycles. The lysate was spun and the supernatant was collected and used for b-galactosidase activity and CAT assays. The pellets were resuspended in high salt buer (20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), pH 7.9, 1 mM EDTA, 1 mM EGTA, 420 mM NaCl, 20% glycerol, 1 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 20 mM NaF, 1 mM DTT and 0.5 mM PMSF) as crude nuclear extract for DNA mobility shift assay. The amount of cytoplasmic extract used in each CAT assay was normalized with equivalent b-galactosidase activity. Acetylated and nonacetylated forms of [ 14 C]chloramphenicol were separated by thin layer chromatography, followed by autoradiography and quanti®cation using a Bio-Rad GS700 Imaging Densitometer. Each transfection and CAT assay was repeated at least three times. The crude nuclear extracts were used for the mobility shift DNA binding assay with hSIE as a probe under conditions described previously except in the absence of salt in the binding buer . The competition assay was performed with 100-fold excess of unlabeled oligonucleotides of either wild type or the mutant hSIEs in which the core hSIE sequence TTCCCGTAA was mutated to TTCACGTCA (M1) or TTCCAGGAG (M2).
Antibodies, immunoprecipitation and immunoblotting
Antibodies against Stat1, Stat3, ERK1, and ERK2 were purchased from Transduction Laboratories (Lexington, KY), and Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antiphosphotyrosine antibody, 4G10, was purchased from Upstate Biotechnology Incorporated (UBI) (Lake Placid, NY, USA). Polyclonal antibody against GST fusion protein of Stat3 COOH-terminus was produced as described previously .
The COS-1 cells were co-transfected with 5 mg of Stat3 expression plasmids, and 5 mg of plasmids expressing either Src, Jak2 or ERK2. Preparation of total cell lysates, immunoprecipitation (IP) and immunoblotting (Blot) were performed as described previously .
Separation of nuclear and cytoplasmic components
The nuclear and cytoplasmic fractions were separated as described previously (Cao et al., 1993) with minor modi®cations. Cells were washed with PBS three times, resuspended in Buer A containing 10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT, 1 mM PMSF and 0.5 mM Nonidet P-40 with protease and phosphatase inhibitors, incubated on ice for 10 min, and homogenized in a Dounce homogenizer with 25 strokes. The nuclei were removed by centrifugation and the supernatant was collected as cytoplasmic portion. The nuclear proteins were extracted in RIPA and used for IP/ Blot experiments.
32 P-orthophosphate labeling, phosphoamino acid analysis and peptide mapping COS-1 cells were transfected and labeled for 4 h before harvesting as described previously (Jain et al., 1996) except that 32 P-orthophosphate was used at a ®nal concentration of 1 mCi/ml. Cells were lysed in RIPA buer with appropriate protease and phosphatase inhibitors. Transfected Stat3 was immunoprecipitated from the lysates by anti-Stat3 antibody and the immunoprecipitates were washed two times with RIPA buer and two times with PBS. The proteins were separated by 7.5% SDS ± PAGE and transferred to a nitrocellulose membrane. The Stat3 band, located after an overnight exposure to X-ray ®lm, was excised, digested with trypsin and subjected to peptide mapping. The phosphopeptide was eluted from the TLC plate with 20% acetonitrile and used for phosphoamino acid analysis as described (Boyle et al., 1991) .
